FDA's Hasty Policymaking Approach Faces APA Challenges

The FDA's most attention-grabbing actions in recent months have not come via guidance or regulation, but instead through podium-based policymaking and press releases, bypassing traditional notice-and-comment procedures. Of counsel Rachel Turow discusses how these policy changes may violate the Administrative Procedure Act and explores implications for future regulatory challenges.